It is more than 50 years since the Epstein–Barr virus (EBV), the first human tumour virus, was discovered. EBV has subsequently been found to be associated with a diverse range of tumours of both lymphoid and epithelial origin. Progress in the molecular analysis of EBV has revealed fundamental mechanisms of more general relevance to the oncogenic process. This Timeline article highlights key milestones in the 50-year history of EBV and discusses how this virus provides a paradigm for exploiting insights at the molecular level in the diagnosis, treatment and prevention of cancer.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
Programmable CRISPR-Cas9 microneedle patch for long-term capture and real-time monitoring of universal cell-free DNA
Nature Communications Open Access 09 July 2022
Circulating virome and inflammatory proteome in patients with ST-elevation myocardial infarction and primary ventricular fibrillation
Scientific Reports Open Access 12 May 2022
CPT1A-mediated fatty acid oxidation promotes cell proliferation via nucleoside metabolism in nasopharyngeal carcinoma
Cell Death & Disease Open Access 11 April 2022
Subscribe to Journal
Get full journal access for 1 year
only $8.25 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
De Martel, C. et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol. 13, 607–615 (2012).
Khan, G. & Hashim, M. J. Global burden of deaths from Epstein–Barr virus: attributable malignancies 1990–2010. Infect. Agent. Cancer 9, 38 (2014).
Crawford, D. H., Rickinson, A. B. & Johannessen, I. in Cancer Virus: The Story of Epstein–Barr Virus (Oxford Univ. Press, 2014).
Tsao, S. W., Tsang, C. M., To, K. F. & Lo, K. W. The role of Epstein–Barr virus in epithelial malignancies. J. Pathol. 235, 323–333 (2015).
Pasteur, L. Inaugural address as newly appointed Professor and Dean at the opening of the new Faculte des Sciences, Univ. Lille (7 Dec 1854).
Epstein, M. A. On the discovery of Epstein–Barr virus: a memoir. Epstein–Barr Virus Rep. 6, 58–63 (1999).
Epstein, M. A., Achong, B. G. & Barr, Y. M. Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet 1, 702–703 (1964).
Epstein, M. A. Citation classic – Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Curr. Contents Life Sci. 14, 156 (1979).
Pope, J. H., Achong, B. G., Epstein, M. A. & Biddulph, J. Burkitt lymphoma in New Guinea: establishment of a line of lymphoblasts in vitro and description of their fine structure. J. Natl Cancer Inst. 39, 933–945 (1967).
Henle, W., Diehl, V., Kohn, G., Zur Hausen, H. & Henle, G. Herpes-type virus and chromosome marker in normal leukocytes after growth with irradiated Burkitt cells. Science 157, 1064–1065 (1967).
Pope, J. H. Establishment of cell lines from peripheral leucocytes in infectious mononucleosis. Nature 216, 810–811 (1967).
Pope, J. H., Horne, M. K. & Scott, W. Transformation of foetal human keukocytes in vitro by filtrates of a human leukaemic cell line containing herpes-like virus. Int. J. Cancer 3, 857–866 (1968).
Henderson, E., Miller, G., Robinson, J. & Heston, L. Efficiency of transformation of lymphocytes by Epstein–Barr virus. Virology 76, 152–163 (1977).
Sugden, B. & Mark, W. Clonal transformation of adult human leukocytes by Epstein–Barr virus. J. Virol. 23, 503–508 (1977).
Thorley-Lawson, D. A. & Allday, M. J. The curious case of the tumour virus: 50 years of Burkitt's lymphoma. Nat. Rev. Microbiol. 6, 913–924 (2008).
Baer, R. et al. DNA sequence and expression of the B95-8 Epstein–Barr virus genome. Nature 310, 207–211 (1984).
Dambaugh, T., Hennessy, K., Chamnankit, L. & Kieff, E. U2 region of Epstein–Barr virus DNA may encode Epstein–Barr nuclear antigen 2. Proc. Natl Acad. Sci. USA 81, 7632–7636 (1984).
Sample, J. et al. Epstein–Barr virus types 1 and 2 differ in their EBNA-3A, EBNA-3B, and EBNA-3C genes. J. Virol. 64, 4084–4092 (1990).
de Jesus, O. et al. Updated Epstein–Barr virus (EBV) DNA sequence and analysis of a promoter for the BART (CST, BARF0) RNAs of EBV. J. Gen. Virol. 84, 1443–1450 (2003).
Zeng, M. S. et al. Genomic sequence analysis of Epstein–Barr virus strain GD1 from a nasopharyngeal carcinoma patient. J. Virol. 79, 15323–15330 (2005).
Dolan, A., Addison, C., Gatherer, D., Davison, A. J. & McGeoch, D. J. The genome of Epstein–Barr virus type 2 strain AG876. Virology 350, 164–170 (2006).
Liu, P. et al. Direct sequencing and characterization of a clinical isolate of Epstein–Barr virus from nasopharyngeal carcinoma tissue by using next-generation sequencing technology. J. Virol. 85, 11291–11299 (2011).
Kwok, H. et al. Genomic sequencing and comparative analysis of Epstein–Barr virus genome isolated from primary nasopharyngeal carcinoma biopsy. PLoS ONE 7, e36939 (2012).
Lin, Z. et al. Whole-genome sequencing of the Akata and Mutu Epstein–Barr virus strains. J. Virol. 87, 1172–1182 (2013).
Tsai, M. H. et al. Spontaneous lytic replication and epitheliotropism define an Epstein–Barr virus strain found in carcinomas. Cell Rep. 5, 458–470 (2013).
Lei, H. et al. Identification and characterization of EBV genomes in spontaneously immortalized human peripheral blood B lymphocytes by NGS technology. BMC Genomics 14, 804 (2013).
Kwok, H. et al. Genomic diversity of Epstein–Barr virus genomes isolated from primary nasopharyngeal carcinoma biopsy samples. J. Virol. 88, 10662–10672 (2014).
Santpere, G. et al. Genome-wide analysis of wild-type Epstein–Barr virus genomes derived from healthy individuals of the 1,000 Genomes project. Genome Biol. Evol. 6, 846–860 (2014).
Palser, A. L. et al. Genome diversity of Epstein–Barr virus from multiple tumor types and normal infection. J. Virol. 89, 5222–5237 (2015).
Rowe, M. et al. Differences in B cell growth phenotype reflect novel patterns of Epstein–Barr virus latent gene expression in Burkitt's lymphoma cells. EMBO J. 6, 2743–2751 (1987).
Rowe, M., Lear, A. L., Croom-Carter, D., Davies, A. H. & Rickinson, A. B. Three pathways of Epstein–Barr virus gene activation from EBNA1-positive latency in B lymphocytes. J. Virol. 66, 122–131 (1992).
Young, L. S. et al. Epstein–Barr virus gene expression in nasopharyngeal carcinoma. J. Gen. Virol. 69, 1051–1065 (1988).
Imai, S. et al. Gastric carcinoma: monoclonal epithelial malignant cells expressing Epstein–Barr virus latent infection protein. Proc. Natl Acad. Sci. USA 91, 9131–9135 (1994).
zur Hausen, H., O'Neill, F. J., Freese, U. K. & Hecker, E. Persisting oncogenic herpesvirus induced by the tumour promoter TPA. Nature 272, 373–375 (1978).
Kallin, B., Luka, J. & Klein, G. Immunochemical characterization of Epstein–Barr virus-associated early and late antigens in n-butyrate-treated P3HR-1 cells. J. Virol. 32, 710–716 (1979).
Countryman, J. & Miller, G. Activation of expression of latent Epstein–Barr herpesvirus after gene transfer with a small cloned subfragment of heterogeneous viral DNA. Proc. Natl Acad. Sci. USA 82, 4085–4089 (1985).
Bhende, P. M., Dickerson, S. J., Sun, X., Feng, W. H. & Kenney, S. C. X-Box-binding protein 1 activates lytic Epstein–Barr virus gene expression in combination with protein kinase D. J. Virol. 81, 7363–7370 (2007).
Sun, C. C. & Thorley-Lawson, D. A. Plasma cell-specific transcription factor XBP-1s binds to and transactivates the Epstein–Barr virus BZLF1 promoter. J. Virol. 81, 13566–13577 (2007).
Temple, R. M. et al. Efficient replication of Epstein–Barr virus in stratified epithelium in vitro. Proc. Natl Acad. Sci. USA 111, 16544–16549 (2014).
Old, L. J. et al. Precipitating antibody in human serum to an antigen present in cultured Burkitt's lymphoma cells. Proc. Natl Acad. Sci. USA 56, 1699–1704 (1966).
Levy, J. A. & Henle, G. Indirect immunofluorescence tests with sera from African children and cultured Burkitt lymphoma cells. J. Bacteriol. 92, 275–276 (1966).
Henle, G. & Henle, W. Immunofluorescence in cells derived from Burkitt's lymphoma. J. Bacteriol. 91, 1248–1256 (1966).
Henle, G. et al. Antibodies to Epstein–Barr virus in Burkitt's lymphoma and control groups. J. Natl Cancer Inst. 43, 1147–1157 (1969).
de-The, G. et al. Epidemiological evidence for causal relationship between Epstein–Barr virus and Burkitt's lymphoma from Ugandan prospective study. Nature 274, 756–761 (1978).
Whittle, H. C. et al. T-cell control of Epstein–Barr virus-infected B cells is lost during P. falciparum malaria. Nature 312, 449–450 (1984).
Moormann, A. M. et al. Exposure to holoendemic malaria results in suppression of Epstein–Barr virus-specific T cell immunosurveillance in Kenyan children. J. Infect. Dis. 195, 799–808 (2007).
Moormann, A. M., Snider, C. J. & Chelimo, K. The company malaria keeps: how co-infection with Epstein–Barr virus leads to endemic Burkitt lymphoma. Curr. Opin. Infect. Dis. 24, 435–441 (2011).
Horne-Debets, J. M. et al. PD-1 dependent exhaustion of CD8+ T cells drives chronic malaria. Cell Rep. 5, 1204–1213 (2013).
Moss, D. J. et al. A comparison of Epstein–Barr virus-specific T-cell immunity in malaria-endemic and -nonendemic regions of Papua New Guinea. Int. J. Cancer 31, 727–732 (1983).
Njie, R. et al. The effects of acute malaria on Epstein–Barr virus (EBV) load and EBV-specific T cell immunity in Gambian children. J. Infect. Dis. 199, 31–38 (2009).
Torgbor, C. et al. A multifactorial role for P. falciparum malaria in endemic Burkitt's lymphoma pathogenesis. PLoS Pathog. 10, e1004170 (2014).
Wilmore, J. R. et al. AID expression in peripheral blood of children living in a malaria holoendemic region is associated with changes in B cell subsets and Epstein–Barr virus. Int. J. Cancer 136, 1371–1380 (2015).
MacNeil, A., Sumba, O. P., Lutzke, M. L., Moormann, A. & Rochford, R. Activation of the Epstein–Barr virus lytic cycle by the latex of the plant Euphorbia tirucalli. Br. J. Cancer 88, 1566–1569 (2003).
Mannucci, S. et al. EBV reactivation and chromosomal polysomies: Euphorbia tirucalli as a possible cofactor in endemic Burkitt lymphoma. Adv. Hematol. 2012, 149780 (2012).
zur Hausen, H. et al. EBV DNA in biopsies of Burkitt tumours and anaplastic carcinomas of the nasopharynx. Nature 228, 1056–1058 (1970).
Reedman, B. M. et al. Epstein–Barr virus-associated complement-fixing and nuclear antigens in Burkitt lymphoma biopsies. Int. J. Cancer 13, 755–763 (1974).
Dillner, J. et al. Antibodies against a synthetic peptide identify the Epstein–Barr virus-determined nuclear antigen. Proc. Natl Acad. Sci. USA 81, 4652–4656 (1984).
Dillner, J., Kallin, B., Ehlin-Henriksson, B., Timar, L. & Klein, G. Characterization of a second Epstein–Barr virus-determined nuclear antigen associated with the BamHI WYH region of EBV DNA. Int. J. Cancer 35, 359–366 (1985).
Manolov, G. & Manolova, Y. Marker band in one chromosome 14 from Burkitt lymphomas. Nature 237, 33–34 (1972).
Zech, L., Haglund, U., Nilsson, K. & Klein, G. Characteristic chromosomal abnormalities in biopsies and lymphoid-cell lines from patients with Burkitt and non-Burkitt lymphomas. Int. J. Cancer 17, 47–56 (1976).
Bernheim, A., Berger, R. & Lenoir, G. [Translocations t(2;8) and t(8;22) in continuous cell lines of African Burkitt's lymphoma]. C. R. Seances Acad. Sci. D 291, 237–239 (1980).
Erikson, J., ar-Rushdi, A., Drwinga, H. L., Nowell, P. C. & Croce, C. M. Transcriptional activation of the translocated c-myc oncogene in Burkitt lymphoma. Proc. Natl Acad. Sci. USA 80, 820–824 (1983).
Armelin, H. A. et al. Functional role for c-myc in mitogenic response to platelet-derived growth factor. Nature 310, 655–660 (1984).
Einat, M., Resnitzky, D. & Kimchi, A. Close link between reduction of c-myc expression by interferon and, G0/G1 arrest. Nature 313, 597–600 (1985).
Evan, G. I. et al. Induction of apoptosis in fibroblasts by c-myc protein. Cell 69, 119–128 (1992).
Milner, A. E., Grand, R. J., Waters, C. M. & Gregory, C. D. Apoptosis in Burkitt lymphoma cells is driven by c-myc. Oncogene 8, 3385–3391 (1993).
Shimizu, N., Tanabe-Tochikura, A., Kuroiwa, Y. & Takada, K. Isolation of Epstein–Barr virus (EBV)-negative cell clones from the EBV-positive Burkitt's lymphoma (BL) line Akata: malignant phenotypes of BL cells are dependent on EBV. J. Virol. 68, 6069–6073 (1994).
Kennedy, G., Komano, J. & Sugden, B. Epstein–Barr virus provides a survival factor to Burkitt's lymphomas. Proc. Natl Acad. Sci. USA 100, 14269–14274 (2003).
Ruf, I. K. et al. Epstein–Barr virus regulates c-MYC, apoptosis, and tumorigenicity in Burkitt lymphoma. Mol. Cell. Biol. 19, 1651–1660 (1999).
Komano, J., Maruo, S., Kurozumi, K., Oda, T. & Takada, K. Oncogenic role of Epstein–Barr virus-encoded RNAs in Burkitt's lymphoma cell line Akata. J. Virol. 73, 9827–9831 (1999).
Jochner, N. et al. Epstein–Barr virus nuclear antigen 2 is a transcriptional suppressor of the immunoglobulin mu gene: implications for the expression of the translocated c-myc gene in Burkitt's lymphoma cells. EMBO J. 15, 375–382 (1996).
Pajic, A. et al. Antagonistic effects of c-myc and Epstein–Barr virus latent genes on the phenotype of human B cells. Int. J. Cancer 93, 810–816 (2001).
Kelly, G., Bell, A. & Rickinson, A. Epstein–Barr virus-associated Burkitt lymphomagenesis selects for downregulation of the nuclear antigen EBNA2. Nat. Med. 8, 1098–1104 (2002).
Kelly, G. L. et al. Epstein–Barr virus nuclear antigen 2 (EBNA2) gene deletion is consistently linked with EBNA3A, -3B, and -3C expression in Burkitt's lymphoma cells and with increased resistance to apoptosis. J. Virol. 79, 10709–10717 (2005).
Anderton, E. et al. Two Epstein–Barr virus (EBV) oncoproteins cooperate to repress expression of the proapoptotic tumour-suppressor Bim: clues to the pathogenesis of Burkitt's lymphoma. Oncogene 27, 421–433 (2008).
Kelly, G. L. et al. An Epstein–Barr virus anti-apoptotic protein constitutively expressed in transformed cells and implicated in Burkitt lymphomagenesis: the Wp/BHRF1 link. PLoS Pathog. 5, e1000341 (2009).
Tierney, R. J., Shannon-Lowe, C. D., Fitzsimmons, L., Bell, A. I. & Rowe, M. Unexpected patterns of Epstein–Barr virus transcription revealed by a high throughput PCR array for absolute quantification of viral mRNA. Virology 474, 117–130 (2015).
Henle, G., Henle, W. & Diehl, V. Relation of Burkitt's tumor-associated herpes-type virus to infectious mononucleosis. Proc. Natl Acad. Sci. USA 59, 94–101 (1968).
Niederman, J. C., Miller, G., Pearson, H. A., Pagano, J. S. & Dowaliby, J. M. Infectious mononucleosis. Epstein–Barr-virus shedding in saliva and the oropharynx. N. Engl. J. Med. 294, 1355–1359 (1976).
Greenspan, J. S. et al. Replication of Epstein–Barr virus within the epithelial cells of oral “hairy” leukoplakia, an AIDS-associated lesion. N. Engl. J. Med. 313, 1564–1571 (1985).
Babcock, G. J., Decker, L. L., Volk, M. & Thorley-Lawson, D. A. EBV persistence in memory B cells in vivo. Immunity 9, 395–404 (1998).
Kurth, J. et al. EBV-infected B cells in infectious mononucleosis: viral strategies for spreading in the B cell compartment and establishing latency. Immunity 13, 485–495 (2000).
Kurth, J., Hansmann, M. L., Rajewsky, K. & Kuppers, R. Epstein–Barr virus-infected B cells expanding in germinal centers of infectious mononucleosis patients do not participate in the germinal center reaction. Proc. Natl Acad. Sci. USA 100, 4730–4735 (2003).
Thorley-Lawson, D. A. & Gross, A. Persistence of the Epstein–Barr virus and the origins of associated lymphomas. N. Engl. J. Med. 350, 1328–1337 (2004).
Gires, O. et al. Latent membrane protein 1 of Epstein–Barr virus mimics a constitutively active receptor molecule. EMBO J. 16, 6131–6140 (1997).
Caldwell, R. G., Wilson, J. B., Anderson, S. J. & Longnecker, R. Epstein–Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. Immunity 9, 405–411 (1998).
Babcock, G. J., Hochberg, D. & Thorley-Lawson, A. D. The expression pattern of Epstein–Barr virus latent genes in vivo is dependent upon the differentiation stage of the infected B cell. Immunity 13, 497–506 (2000).
Thorley-Lawson, D. A. Epstein–Barr virus: exploiting the immune system. Nat. Rev. Immunol. 1, 75–82 (2001).
Panagopoulos, D., Victoratos, P., Alexiou, M., Kollias, G. & Mosialos, G. Comparative analysis of signal transduction by CD40 and the Epstein–Barr virus oncoprotein LMP1 in vivo. J. Virol. 78, 13253–13261 (2004).
Swanson-Mungerson, M. A., Caldwell, R. G., Bultema, R. & Longnecker, R. Epstein–Barr virus LMP2A alters in vivo and in vitro models of B-cell anergy, but not deletion, in response to autoantigen. J. Virol. 79, 7355–7362 (2005).
Thorley-Lawson, D. A., Duca, K. A. & Shapiro, M. Epstein–Barr virus: a paradigm for persistent infection — for real and in virtual reality. Trends Immunol. 29, 195–201 (2008).
Roughan, J. E. & Thorley-Lawson, D. A. The intersection of Epstein–Barr virus with the germinal center. J. Virol. 83, 3968–3976 (2009).
Roughan, J. E., Torgbor, C. & Thorley-Lawson, D. A. Germinal center B cells latently infected with Epstein–Barr virus proliferate extensively but do not increase in number. J. Virol. 84, 1158–1168 (2010).
Laichalk, L. L. & Thorley-Lawson, D. A. Terminal differentiation into plasma cells initiates the replicative cycle of Epstein–Barr virus in vivo. J. Virol. 79, 1296–1307 (2005).
Sheldon, P. J., Hemsted, E. H., Papamichail, M. & Holborow, E. J. Thymic origin of atypical lymphoid cells in infectious mononucleosis. Lancet 1, 1153–1155 (1973).
Pattengale, P. K., Smith, R. W. & Perlin, E. Atypical lymphocytes in acute infectious mononucleosis. Identification by multiple T and B lymphocyte markers. N. Engl. J. Med. 291, 1145–1148 (1974).
Moss, D. J., Rickinson, A. B. & Pope, J. H. Long-term T-cell-mediated immunity to Epstein–Barr virus in man. I. Complete regression of virus-induced transformation in cultures of seropositive donor leukocytes. Int. J. Cancer 22, 662–668 (1978).
Rickinson, A. B., Moss, D. J. & Pope, J. H. Long-term C-cell-mediated immunity to Epstein–Barr virus in man. II. Components necessary for regression in virus-infected leukocyte cultures. Int. J. Cancer 23, 610–617 (1979).
Moss, D. J. et al. Cytotoxic T-cell clones discriminate between A- and B-type Epstein–Barr virus transformants. Nature 331, 719–721 (1988).
Burrows, S. R., Sculley, T. B., Misko, I. S., Schmidt, C. & Moss, D. J. An Epstein–Barr virus-specific cytotoxic T cell epitope in EBV nuclear antigen 3 (EBNA 3). J. Exp. Med. 171, 345–349 (1990).
Kanekiyo, M. et al. Rational design of an Epstein–Barr virus vaccine targeting the receptor-binding site. Cell 162, 1090–1100 (2015).
Hui, E. P. et al. Phase I trial of recombinant modified vaccinia ankara encoding Epstein–Barr viral tumor antigens in nasopharyngeal carcinoma patients. Cancer Res. 73, 1676–1688 (2013).
Sokal, E. M. et al. Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein–Barr virus vaccine in healthy young adults. J. Infect. Dis. 196, 1749–1753 (2007).
Doak, P. B., Montgomerie, J. Z., North, J. D. & Smith, F. Reticulum cell sarcoma after renal homotransplantation and azathioprine and prednisone therapy. Br. Med. J. 4, 746–748 (1968).
Penn, I., Hammond, W., Brettschneider, L. & Starzl, T. E. Malignant lymphomas in transplantation patients. Transplant. Proc. 1, 106–112 (1969).
Nagington, J. & Gray, J. Cyclosporin A immunosuppression, Epstein–Barr antibody, and lymphoma. Lancet 1, 536–537 (1980).
Crawford, D. H. et al. Epstein Barr virus nuclear antigen positive lymphoma after cyclosporin A treatment in patient with renal allograft. Lancet 1, 1355–1356 (1980).
Hanto, D. W., Sakamoto, K., Purtilo, D. T., Simmons, R. L. & Najarian, J. S. The Epstein–Barr virus in the pathogenesis of posttransplant lymphoproliferative disorders. Clinical, pathologic, and virologic correlation. Surgery 90, 204–213 (1981).
Saemundsen, A. K. et al. Documentation of Epstein–Barr virus infection in immunodeficient patients with life-threatening lymphoproliferative diseases by Epstein–Barr virus complementary RNA/DNA and viral DNA/DNA hybridization. Cancer Res. 41, 4237–4242 (1981).
Hanto, D. W. et al. Epstein–Barr virus (EBV) induced polyclonal and monoclonal B-cell lymphoproliferative diseases occurring after renal transplantation. Clinical, pathologic, and virologic findings and implications for therapy. Ann. Surg. 198, 356–369 (1983).
Schubach, W. H., Hackman, R., Neiman, P. E., Miller, G. & Thomas, E. D. A monoclonal immunoblastic sarcoma in donor cells bearing Epstein–Barr virus genomes following allogeneic marrow grafting for acute lymphoblastic leukemia. Blood 60, 180–187 (1982).
Dotti, G. et al. Lymphomas occurring late after solid-organ transplantation: influence of treatment on the clinical outcome. Transplantation 74, 1095–1102 (2002).
Rea, D. et al. Epstein–Barr virus latent and replicative gene expression in post-transplant lymphoproliferative disorders and AIDS-related non-Hodgkin's lymphomas. French Study Group of Pathology for HIV-associated Tumors. Ann. Oncol. 5 (Suppl. 1), 113–116 (1994).
Kanakry, J. A. & Ambinder, R. F. EBV-related lymphomas: new approaches to treatment. Curr. Treat. Opt. Oncol. 14, 224–236 (2013).
Simmons, R. L. & Najarian, J. S. Immunosuppression and malignant neoplasms. N. Engl. J. Med. 283, 934–935 (1970).
Starzl, T. E. et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1, 583–587 (1984).
Rooney, C. M. et al. Use of gene-modified virus-specific T lymphocytes to control Epstein–Barr-virus-related lymphoproliferation. Lancet 345, 9–13 (1995).
Heslop, H. E. et al. Long-term restoration of immunity against Epstein–Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat. Med. 2, 551–555 (1996).
Bollard, C. M. et al. Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein–Barr virus latent membrane proteins. J. Clin. Oncol. 32, 798–808 (2014).
Oyama, T. et al. Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: a study of 96 patients. Clin. Cancer Res. 13, 5124–5132 (2007).
Purtilo, D. T., Cassel, C. K., Yang, J. P. & Harper, R. X-Linked recessive progressive combined variable immunodeficiency (Duncan's disease). Lancet 1, 935–940 (1975).
Seemayer, T. A. et al. X-Linked lymphoproliferative disease: twenty-five years after the discovery. Pediatr. Res. 38, 471–478 (1995).
Coffey, A. J. et al. Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene. Nat. Genet. 20, 129–135 (1998).
Nichols, K. E. et al. Inactivating mutations in an SH2 domain-encoding gene in X-linked lymphoproliferative syndrome. Proc. Natl Acad. Sci. USA 95, 13765–13770 (1998).
Sayos, J. et al. The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM. Nature 395, 462–469 (1998).
Hislop, A. D. et al. Impaired Epstein–Barr virus-specific CD8+ T-cell function in X-linked lymphoproliferative disease is restricted to SLAM family-positive B-cell targets. Blood 116, 3249–3257 (2010).
MacMahon, B. Epidemiology of Hodgkin's disease. Cancer Res. 26, 1189–1201 (1966).
Correa, P. & O'Conor, G. T. Epidemiologic patterns of Hodgkin's disease. Int. J. Cancer 8, 192–201 (1971).
Connelly, R. R. & Christine, B. W. A cohort study of cancer following infectious mononucleosis. Cancer Res. 34, 1172–1178 (1974).
Rosdahl, N., Larsen, S. O. & Clemmesen, J. Hodgkin's disease in patients with previous infectious mononucleosis: 30 years' experience. Br. Med. J. 2, 253–256 (1974).
Poppema, S., van Imhoff, G., Torensma, R. & Smit, J. Lymphadenopathy morphologically consistent with Hodgkin's disease associated with Epstein–Barr virus infection. Am. J. Clin. Pathol. 84, 385–390 (1985).
Weiss, L. M., Strickler, J. G., Warnke, R. A., Purtilo, D. T. & Sklar, J. Epstein–Barr viral DNA in tissues of Hodgkin's disease. Am. J. Pathol. 129, 86–91 (1987).
Weiss, L. M., Movahed, L. A., Warnke, R. A. & Sklar, J. Detection of Epstein–Barr viral genomes in Reed–Sternberg cells of Hodgkin's disease. N. Engl. J. Med. 320, 502–506 (1989).
Wu, T. C. et al. Detection of EBV gene expression in Reed–Sternberg cells of Hodgkin's disease. Int. J. Cancer 46, 801–804 (1990).
Kuppers, R. et al. Hodgkin disease: Hodgkin and Reed–Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development. Proc. Natl Acad. Sci. USA 91, 10962–10966 (1994).
Brauninger, A. et al. Molecular biology of Hodgkin's and Reed/Sternberg cells in Hodgkin's lymphoma. Int. J. Cancer 118, 1853–1861 (2006).
Chaganti, S. et al. Epstein–Barr virus infection in vitro can rescue germinal center B cells with inactivated immunoglobulin genes. Blood 106, 4249–4252 (2005).
Mancao, C., Altmann, M., Jungnickel, B. & Hammerschmidt, W. Rescue of “crippled” germinal center B cells from apoptosis by Epstein–Barr virus. Blood 106, 4339–4344 (2005).
Bechtel, D., Kurth, J., Unkel, C. & Kuppers, R. Transformation of BCR-deficient germinal-center B cells by EBV supports a major role of the virus in the pathogenesis of Hodgkin and posttransplantation lymphomas. Blood 106, 4345–4350 (2005).
Pallesen, G., Hamilton-Dutoit, S. J., Rowe, M. & Young, L. S. Expression of Epstein–Barr virus latent gene products in tumour cells of Hodgkin's disease. Lancet 337, 320–322 (1991).
Murray, P. G., Young, L. S., Rowe, M. & Crocker, J. Immunohistochemical demonstration of the Epstein–Barr virus-encoded latent membrane protein in paraffin sections of Hodgkin's disease. J. Pathol. 166, 1–5 (1992).
Deacon, E. M. et al. Epstein–Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells. J. Exp. Med. 177, 339–349 (1993).
Murray, P. G., Constandinou, C. M., Crocker, J., Young, L. S. & Ambinder, R. F. Analysis of major histocompatibility complex class I, TAP expression, and LMP2 epitope sequence in Epstein–Barr virus-positive Hodgkin's disease. Blood 92, 2477–2483 (1998).
Alber, G. et al. Molecular mimicry of the antigen receptor signalling motif by transmembrane proteins of the Epstein–Barr virus and the bovine leukaemia virus. Curr. Biol. 3, 333–339 (1993).
Mosialos, G. et al. The Epstein–Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell 80, 389–399 (1995).
Hjalgrim, H. et al. Infectious mononucleosis, childhood social environment, and risk of Hodgkin lymphoma. Cancer Res. 67, 2382–2388 (2007).
Hjalgrim, H. et al. HLA-A alleles and infectious mononucleosis suggest a critical role for cytotoxic T-cell response in EBV-related Hodgkin lymphoma. Proc. Natl Acad. Sci. USA 107, 6400–6405 (2010).
Diepstra, A. et al. Association with HLA class I in Epstein–Barr-virus-positive and with HLA class III in Epstein–Barr-virus-negative Hodgkin's lymphoma. Lancet 365, 2216–2224 (2005).
Doll, D. C. & List, A. F. Burkitt's lymphoma in a homosexual. Lancet 1, 1026–1027 (1982).
Ziegler, J. L. et al. Outbreak of Burkitt's-like lymphoma in homosexual men. Lancet 2, 631–633 (1982).
Chaganti, R. S. et al. Specific translocations characterize Burkitt's-like lymphoma of homosexual men with the acquired immunodeficiency syndrome. Blood 61, 1265–1268 (1983).
Moir, S. & Fauci, A. S. Insights into B cells and HIV-specific B-cell responses in HIV-infected individuals. Immunol. Rev. 254, 207–224 (2013).
Haas, A., Zimmermann, K. & Oxenius, A. Antigen-dependent and -independent mechanisms of T and B cell hyperactivation during chronic HIV-1 infection. J. Virol. 85, 12102–12113 (2011).
Biggar, R. J. et al. Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. Blood 108, 3786–3791 (2006).
Jones, J. F. et al. T-Cell lymphomas containing Epstein–Barr viral DNA in patients with chronic Epstein–Barr virus infections. N. Engl. J. Med. 318, 733–741 (1988).
Kikuta, H. et al. Epstein–Barr virus genome-positive T lymphocytes in a boy with chronic active EBV infection associated with Kawasaki-like disease. Nature 333, 455–457 (1988).
Harabuchi, Y. et al. Epstein–Barr virus in nasal T-cell lymphomas in patients with lethal midline granuloma. Lancet 335, 128–130 (1990).
Cohen, J. I. Optimal treatment for chronic active Epstein–Barr virus disease. Pediatr. Transplant. 13, 393–396 (2009).
Au, W. Y. et al. Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Blood 113, 3931–3937 (2009).
Chiang, A. K., Tao, Q., Srivastava, G. & Ho, F. C. Nasal NK- and T-cell lymphomas share the same type of Epstein–Barr virus latency as nasopharyngeal carcinoma and Hodgkin's disease. Int. J. Cancer 68, 285–290 (1996).
Coleman, C. B. et al. Epstein–Barr virus type 2 latently infects T cells, inducing an atypical activation characterized by expression of lymphotactic cytokines. J. Virol. 89, 2301–2312 (2015).
Ng, S. B. et al. Activated oncogenic pathways and therapeutic targets in extranodal nasal-type NK/T cell lymphoma revealed by gene expression profiling. J. Pathol. 223, 496–510 (2011).
de Schryver, A. et al. Epstein–Barr virus-associated antibody patterns in carcinoma of the post-nasal space. Clin. Exp. Immunol. 5, 443–459 (1969).
Henle, W. et al. Antibodies to Epstein–Barr virus in nasopharyngeal carcinoma, other head and neck neoplasms, and control groups. J. Natl Cancer Inst. 44, 225–231 (1970).
Henle, W., Ho, J. H., Henle, G., Chau, J. C. & Kwan, H. C. Nasopharyngeal carcinoma: significance of changes in Epstein–Barr virus-related antibody patterns following therapy. Int. J. Cancer 20, 663–672 (1977).
Zeng, Y. et al. Prospective studies on nasopharyngeal carcinoma in Epstein–Barr virus IgA/VCA antibody-positive persons in Wuzhou City, China. Int. J. Cancer 36, 545–547 (1985).
Mutirangura, A. et al. Epstein–Barr viral DNA in serum of patients with nasopharyngeal carcinoma. Clin. Cancer Res. 4, 665–669 (1998).
Lo, Y. M. et al. Quantitative and temporal correlation between circulating cell-free Epstein–Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma. Cancer Res. 59, 5452–5455 (1999).
Wolf, H., zur Hausen, H. & Becker, V. EB viral genomes in epithelial nasopharyngeal carcinoma cells. Nat. New Biol. 244, 245–247 (1973).
Pathmanathan, R., Prasad, U., Sadler, R., Flynn, K. & Raab-Traub, N. Clonal proliferations of cells infected with Epstein–Barr virus in preinvasive lesions related to nasopharyngeal carcinoma. N. Engl. J. Med. 333, 693–698 (1995).
Fahraeus, R. et al. Expression of Epstein–Barr virus-encoded proteins in nasopharyngeal carcinoma. Int. J. Cancer 42, 329–338 (1988).
Brooks, L., Yao, Q. Y., Rickinson, A. B. & Young, L. S. Epstein–Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts. J. Virol. 66, 2689–2697 (1992).
Busson, P. et al. Consistent transcription of the Epstein–Barr virus LMP2 gene in nasopharyngeal carcinoma. J. Virol. 66, 3257–3262 (1992).
Niedobitek, G. et al. Epstein–Barr virus and carcinomas: undifferentiated carcinomas but not squamous cell carcinomas of the nasopharynx are regularly associated with the virus. J. Pathol. 165, 17–24 (1991).
Sheen, T. S., Tsai, C. C., Ko, J. Y., Chang, Y. L. & Hsu, M. M. Undifferentiated carcinoma of the major salivary glands. Cancer 80, 357–363 (1997).
Lo, K. W., Chung, G. T. & To, K. F. Deciphering the molecular genetic basis of NPC through molecular, cytogenetic, and epigenetic approaches. Semin. Cancer Biol. 22, 79–86 (2012).
Jia, W. H. & Qin, H. D. Non-viral environmental risk factors for nasopharyngeal carcinoma: a systematic review. Semin. Cancer Biol. 22, 117–126 (2012).
Young, L. S. & Rickinson, A. B. Epstein–Barr virus: 40 years on. Nat. Rev. Cancer 4, 757–768 (2004).
Lin, D. C. et al. The genomic landscape of nasopharyngeal carcinoma. Nat. Genet. 46, 866–871 (2014).
Shibata, D. & Weiss, L. M. Epstein–Barr virus-associated gastric adenocarcinoma. Am. J. Pathol. 140, 769–774 (1992).
Global Cancer Observatory. Estimated cancer incidence, mortality and prevalence worldwide in 2012. Globocan 2012 Cancer Fact Sheet: Stomach cancer. http://globocan.iarc.fr/old/FactSheets/cancers/stomach-new.asp (2012).
Lee, J. H. et al. Clinicopathological and molecular characteristics of Epstein–Barr virus-associated gastric carcinoma: a meta-analysis. J. Gastroenterol. Hepatol. 24, 354–365 (2009).
Murphy, G., Pfeiffer, R., Camargo, M. C. & Rabkin, C. S. Meta-analysis shows that prevalence of Epstein–Barr virus-positive gastric cancer differs based on sex and anatomic location. Gastroenterology 137, 824–833 (2009).
Lee, H. S., Chang, M. S., Yang, H. K., Lee, B. L. & Kim, W. H. Epstein–Barr virus-positive gastric carcinoma has a distinct protein expression profile in comparison with Epstein−Barr virus-negative carcinoma. Clin. Cancer Res. 10, 1698–1705 (2004).
Schneider, B. G. et al. Loss of p16/CDKN2A tumor suppressor protein in gastric adenocarcinoma is associated with Epstein–Barr virus and anatomic location in the body of the stomach. Hum. Pathol. 31, 45–50 (2000).
Ushiku, T. et al. p73 gene promoter methylation in Epstein–Barr virus-associated gastric carcinoma. Int. J. Cancer 120, 60–66 (2007).
van Rees, B. P. et al. Different pattern of allelic loss in Epstein–Barr virus-positive gastric cancer with emphasis on the p53 tumor suppressor pathway. Am. J. Pathol. 161, 1207–1213 (2002).
Wang, K. et al. Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer. Nat. Genet. 46, 573–582 (2014).
Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513, 202–209 (2014).
zur Hausen, A. et al. Epstein–Barr virus in gastric carcinomas and gastric stump carcinomas: a late event in gastric carcinogenesis. J. Clin. Pathol. 57, 487–491 (2004).
Corvalan, A. et al. Association of a distinctive strain of Epstein–Barr virus with gastric cancer. Int. J. Cancer 118, 1736–1742 (2006).
Muhe, J. & Wang, F. Non-human primate lymphocryptoviruses: past, present, and future. Curr. Top. Microbiol. Immunol. 391, 385–405 (2015).
Miettinen, M. Smooth muscle tumors of soft tissue and non-uterine viscera: biology and prognosis. Mod. Pathol. 27 (Suppl. 1), 17–29 (2014).
Fernandez-Menendez, S., Fernandez-Moran, M., Fernandez-Vega, I., Perez-Alvarez, A. & Villafani-Echazu, J. Epstein–Barr virus and multiple sclerosis. From evidence to therapeutic strategies. J. Neurol. Sci. 361, 213–219 (2016).
Imai, S., Nishikawa, J. & Takada, K. Cell-to-cell contact as an efficient mode of Epstein–Barr virus infection of diverse human epithelial cells. J. Virol. 72, 4371–4378 (1998).
Shannon-Lowe, C. & Rowe, M. Epstein–Barr virus infection of polarized epithelial cells via the basolateral surface by memory B cell-mediated transfer infection. PLoS Pathog. 7, e1001338 (2011).
Ni, C. et al. In-cell infection: a novel pathway for Epstein–Barr virus infection mediated by cell-in-cell structures. Cell Res. 25, 785–800 (2015).
Kanda, T., Furuse, Y., Oshitani, H. & Kiyono, T. Highly efficient CRISPR/Cas9-mediated cloning and functional characterization of gastric cancer-derived Epstein–Barr virus strains. J. Virol. 90, 4383–4393 (2016).
Nakatsuka, S. et al. Pyothorax-associated lymphoma: a review of 106 cases. J. Clin. Oncol. 20, 4255–4260 (2002).
Dojcinov, S. D., Venkataraman, G., Raffeld, M., Pittaluga, S. & Jaffe, E. S. EBV positive mucocutaneous ulcer—a study of 26 cases associated with various sources of immunosuppression. Am. J. Surg. Pathol. 34, 405–417 (2010).
Zhang, G. et al. Circulating Epstein–Barr virus microRNAs miR-BART7 and miR-BART13 as biomarkers for nasopharyngeal carcinoma diagnosis and treatment. Int. J. Cancer 136, E301–E312 (2015).
Yang, X. et al. Epigenetic markers for noninvasive early detection of nasopharyngeal carcinoma by methylation-sensitive high resolution melting. Int. J. Cancer 136, E127–E135 (2015).
Wildeman, M. A. et al. Cytolytic virus activation therapy for Epstein–Barr virus-driven tumors. Clin. Cancer Res. 18, 5061–5070 (2012).
Li, J. H. et al. Efficacy of targeted FasL in nasopharyngeal carcinoma. Mol. Ther. 8, 964–973 (2003).
Lee, E. K. et al. Small molecule inhibition of Epstein–Barr virus nuclear antigen-1 DNA binding activity interferes with replication and persistence of the viral genome. Antiviral Res. 104, 73–83 (2014).
Gianti, E., Messick, T. E., Lieberman, P. M. & Zauhar, R. J. Computational analysis of EBNA1 “druggability” suggests novel insights for Epstein–Barr virus inhibitor design. J. Comput. Aided Mol. Des. 30, 285–303 (2016).
Taylor, G. S. et al. A recombinant modified vaccinia ankara vaccine encoding Epstein–Barr virus (EBV) target antigens: a phase I trial in UK patients with EBV-positive cancer. Clin. Cancer Res. 20, 5009–5022 (2014).
Smith, C. et al. Effective treatment of metastatic forms of Epstein–Barr virus-associated nasopharyngeal carcinoma with a novel adenovirus-based adoptive immunotherapy. Cancer Res. 72, 1116–1125 (2012).
Barton, E. S. et al. Herpesvirus latency confers symbiotic protection from bacterial infection. Nature 447, 326–329 (2007).
Zimber, U. et al. Geographical prevalence of two types of Epstein–Barr virus. Virology 154, 56–66 (1986).
Rickinson, A. B., Young, L. S. & Rowe, M. Influence of the Epstein–Barr virus nuclear antigen EBNA 2 on the growth phenotype of virus-transformed B cells. J. Virol. 61, 1310–1317 (1987).
Yates, J. L., Warren, N. & Sugden, B. Stable replication of plasmids derived from Epstein–Barr virus in various mammalian cells. Nature 313, 812–815 (1985).
Wilson, J. B., Bell, J. L. & Levine, A. J. Expression of Epstein–Barr virus nuclear antigen-1 induces B cell neoplasia in transgenic mice. EMBO J. 15, 3117–3126 (1996).
Gruhne, B. et al. The Epstein–Barr virus nuclear antigen-1 promotes genomic instability via induction of reactive oxygen species. Proc. Natl Acad. Sci. USA 106, 2313–2318 (2009).
Rabson, M., Gradoville, L., Heston, L. & Miller, G. Non-immortalizing P3J-HR-1 Epstein–Barr virus: a deletion mutant of its transforming parent, Jijoye. J. Virol. 44, 834–844 (1982).
Sakai, T. et al. Functional replacement of the intracellular region of the Notch1 receptor by Epstein–Barr virus nuclear antigen 2. J. Virol. 72, 6034–6039 (1998).
Tomkinson, B., Robertson, E. & Kieff, E. Epstein–Barr virus nuclear proteins EBNA-3A and EBNA-3C are essential for B-lymphocyte growth transformation. J. Virol. 67, 2014–2025 (1993).
Parker, G. A. et al. Epstein–Barr virus nuclear antigen (EBNA)3C is an immortalizing oncoprotein with similar properties to adenovirus E1A and papillomavirus E7. Oncogene 13, 2541–2549 (1996).
White, R. E. et al. EBNA3B-deficient EBV promotes B cell lymphomagenesis in humanized mice and is found in human tumors. J. Clin. Invest. 122, 1487–1502 (2012).
Allan, G. J., Inman, G. J., Parker, B. D., Rowe, D. T. & Farrell, P. J. Cell growth effects of Epstein–Barr virus leader protein. J. Gen. Virol. 73, 1547–1551 (1992).
Wang, D., Liebowitz, D. & Kieff, E. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell 43, 831–840 (1985).
Kaye, K. M., Izumi, K. M. & Kieff, E. Epstein–Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. Proc. Natl Acad. Sci. USA 90, 9150–9154 (1993).
Dawson, C. W., Port, R. J. & Young, L. S. The role of the EBV-encoded latent membrane proteins LMP1 and LMP2 in the pathogenesis of nasopharyngeal carcinoma (NPC). Semin. Cancer Biol. 22, 144–153 (2012).
Longnecker, R. & Kieff, E. A second Epstein–Barr virus membrane protein (LMP2) is expressed in latent infection and colocalizes with LMP1. J. Virol. 64, 2319–2326 (1990).
Pearson, G. R. et al. Identification of an Epstein–Barr virus early gene encoding a second component of the restricted early antigen complex. Virology 160, 151–161 (1987).
Henderson, S. et al. Epstein–Barr virus-coded BHRF1 protein, a viral homologue of Bcl-2, protects human B cells from programmed cell death. Proc. Natl Acad. Sci. USA 90, 8479–8483 (1993).
Watanabe, A. et al. Epstein–Barr virus-encoded Bcl-2 homologue functions as a survival factor in Wp-restricted Burkitt lymphoma cell line P3HR-1. J. Virol. 84, 2893–2901 (2010).
Wei, M. X. & Ooka, T. A transforming function of the BARF1 gene encoded by Epstein–Barr virus. EMBO J. 8, 2897–2903 (1989).
Wei, M. X., Moulin, J. C., Decaussin, G., Berger, F. & Ooka, T. Expression and tumorigenicity of the Epstein–Barr virus BARF1 gene in human Louckes B-lymphocyte cell line. Cancer Res. 54, 1843–1848 (1994).
Zhang, C. X., Decaussin, G., Daillie, J. & Ooka, T. Altered expression of two Epstein–Barr virus early genes localized in BamHI-A in nonproducer Raji cells. J. Virol. 62, 1862–1869 (1988).
Seto, E. et al. Epstein–Barr virus (EBV)-encoded BARF1 gene is expressed in nasopharyngeal carcinoma and EBV-associated gastric carcinoma tissues in the absence of lytic gene expression. J. Med. Virol. 76, 82–88 (2005).
Pfeffer, S. et al. Identification of virus-encoded microRNAs. Science 304, 734–736 (2004).
Kozomara, A. & Griffiths-Jones, S. miRBase: annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res. 42, D68–D73 (2014).
Marquitz, A. R. & Raab-Traub, N. The role of miRNAs and EBV BARTs in NPC. Semin. Cancer Biol. 22, 166–172 (2012).
Vereide, D. T. et al. Epstein–Barr virus maintains lymphomas via its miRNAs. Oncogene 33, 1258–1264 (2014).
Shinozaki-Ushiku, A. et al. Profiling of virus-encoded microRNAs in Epstein–Barr virus-associated gastric carcinoma and their roles in gastric carcinogenesis. J. Virol. 89, 5581–5591 (2015).
Kang, D., Skalsky, R. L. & Cullen, B. R. EBV BART microRNAs target multiple pro-apoptotic cellular genes to promote epithelial cell survival. PLoS Pathog. 11, e1004979 (2015).
Lei, T. et al. Targeting of DICE1 tumor suppressor by Epstein–Barr virus-encoded miR-BART3* microRNA in nasopharyngeal carcinoma. Int. J. Cancer 133, 79–87 (2013).
Hsu, C. Y. et al. The Epstein–Barr virus-encoded microRNA MiR-BART9 promotes tumor metastasis by targeting E-cadherin in nasopharyngeal carcinoma. PLoS Pathog. 10, e1003974 (2014).
Kanda, T. et al. Clustered microRNAs of the Epstein–Barr virus cooperatively downregulate an epithelial cell-specific metastasis suppressor. J. Virol. 89, 2684–2697 (2015).
Qiu, J., Smith, P., Leahy, L. & Thorley-Lawson, D. A. The Epstein–Barr virus encoded BART miRNAs potentiate tumor growth in vivo. PLoS Pathog. 11, e1004561 (2015).
Cai, L. et al. Epstein–Barr virus-encoded microRNA BART1 induces tumour metastasis by regulating PTEN-dependent pathways in nasopharyngeal carcinoma. Nature Commun. 6, 7353 (2015).
Wong, A. M., Kong, K. L., Tsang, J. W., Kwong, D. L. & Guan, X. Y. Profiling of Epstein–Barr virus-encoded microRNAs in nasopharyngeal carcinoma reveals potential biomarkers and oncomirs. Cancer 118, 698–710 (2012).
Feederle, R. et al. The members of an Epstein–Barr virus microRNA cluster cooperate to transform B lymphocytes. J. Virol. 85, 9801–9810 (2011).
Rymo, L. Identification of transcribed regions of Epstein–Barr virus DNA in Burkitt lymphoma-derived cells. J. Virol. 32, 8–18 (1979).
Glickman, J. N., Howe, J. G. & Steitz, J. A. Structural analyses of EBER1 and EBER2 ribonucleoprotein particles present in Epstein–Barr virus-infected cells. J. Virol. 62, 902–911 (1988).
Takada, K. Role of EBER and BARF1 in nasopharyngeal carcinoma (NPC) tumorigenesis. Semin. Cancer Biol. 22, 162–165 (2012).
Fixman, E. D., Hayward, G. S. & Hayward, S. D. Trans-acting requirements for replication of Epstein–Barr virus ori-Lyt. J. Virol. 66, 5030–5039 (1992).
Schepers, A., Pich, D. & Hammerschmidt, W. Activation of oriLyt, the lytic origin of DNA replication of Epstein–Barr virus, by BZLF1. Virology 220, 367–376 (1996).
Zhang, Q. et al. Functional and physical interactions between the Epstein–Barr virus (EBV) proteins BZLF1 and BMRF1: effects on EBV transcription and lytic replication. J. Virol. 70, 5131–5142 (1996).
Gao, Z. et al. The Epstein–Barr virus lytic transactivator Zta interacts with the helicase-primase replication proteins. J. Virol. 72, 8559–8567 (1998).
Wen, W. et al. Epstein–Barr virus BZLF1 gene, a switch from latency to lytic infection, is expressed as an immediate-early gene after primary infection of B lymphocytes. J. Virol. 81, 1037–1042 (2007).
Shannon-Lowe, C. et al. Features distinguishing Epstein–Barr virus infections of epithelial cells and B cells: viral genome expression, genome maintenance, and genome amplification. J. Virol. 83, 7749–7760 (2009).
Bhende, P. M., Seaman, W. T., Delecluse, H. J. & Kenney, S. C. The EBV lytic switch protein, Z, preferentially binds to and activates the methylated viral genome. Nat. Genet. 36, 1099–1104 (2004).
Ma, S. D. et al. An Epstein–Barr virus (EBV) mutant with enhanced BZLF1 expression causes lymphomas with abortive lytic EBV infection in a humanized mouse model. J. Virol. 86, 7976–7987 (2012).
Hislop, A. D. et al. A CD8+ T cell immune evasion protein specific to Epstein–Barr virus and its close relatives in Old World primates. J. Exp. Med. 204, 1863–1873 (2007).
Zuo, J. et al. The Epstein–Barr virus G-protein-coupled receptor contributes to immune evasion by targeting MHC class I molecules for degradation. PLoS Pathog. 5, e1000255 (2009).
Rowe, M. et al. Host shutoff during productive Epstein–Barr virus infection is mediated by BGLF5 and may contribute to immune evasion. Proc. Natl Acad. Sci. USA 104, 3366–3371 (2007).
Hong, G. K. et al. Epstein–Barr virus lytic infection contributes to lymphoproliferative disease in a SCID mouse model. J. Virol. 79, 13993–14003 (2005).
Ma, S. D. et al. A new model of Epstein–Barr virus infection reveals an important role for early lytic viral protein expression in the development of lymphomas. J. Virol. 85, 165–177 (2011).
Sato, Y. et al. Degradation of phosphorylated p53 by viral protein-ECS E3 ligase complex. PLoS Pathog. 5, e1000530 (2009).
Chang, Y. H. et al. Epstein–Barr virus BGLF4 kinase retards cellular S-phase progression and induces chromosomal abnormality. PLoS ONE 7, e39217 (2012).
Wu, C. C. et al. Epstein–Barr virus DNase (BGLF5) induces genomic instability in human epithelial cells. Nucleic Acids Res. 38, 1932–1949 (2010).
Lin, Z. et al. Quantitative and qualitative RNA–Seq-based evaluation of Epstein–Barr virus transcription in type I latency Burkitt's lymphoma cells. J. Virol. 84, 13053–13058 (2010).
Young, L. S. & Murray, P. G. Epstein–Barr virus and oncogenesis: from latent genes to tumours. Oncogene 22, 5108–5121 (2003).
Lo, K. W. & Huang, D. P. Genetic and epigenetic changes in nasopharyngeal carcinoma. Semin. Cancer Biol. 12, 451–462 (2002).
Tsang, C. M. et al. Cyclin D1 overexpression supports stable EBV infection in nasopharyngeal epithelial cells. Proc. Natl Acad. Sci. USA 109, E3473–E3482 (2012).
Sheu, L. F. et al. Analysis of bcl-2 expression in normal, inflamed, dysplastic nasopharyngeal epithelia, and nasopharyngeal carcinoma: association with p53 expression. Hum. Pathol. 28, 556–562 (1997).
Chang, J. T. et al. Telomerase activity is frequently found in metaplastic and malignant human nasopharyngeal tissues. Br. J. Cancer 82, 1946–1951 (2000).
Hao, D. et al. Evaluation of E-cadherin, beta-catenin and vimentin protein expression using quantitative immunohistochemistry in nasopharyngeal carcinoma patients. Clin. Invest. Med. 37, E320–E330 (2014).
Li, L., Zhang, Y., Guo, B. B., Chan, F. K. & Tao, Q. Oncogenic induction of cellular high CpG methylation by Epstein–Barr virus in malignant epithelial cells. Chin. J. Cancer 33, 604–608 (2014).
The authors are grateful to A. Bell for help with revisions to the figures. L.S.Y. has been supported by Cancer Research UK. L.F.Y. is supported by High Impact Research Grant UM.C/625/1/HIR/MOHE/DENT/23 from the University of Malaya. P.G.M. is supported by a Bloodwise Programme Grant.
The authors declare no competing financial interests.
About this article
Cite this article
Young, L., Yap, L. & Murray, P. Epstein–Barr virus: more than 50 years old and still providing surprises. Nat Rev Cancer 16, 789–802 (2016). https://doi.org/10.1038/nrc.2016.92
This article is cited by
Virology Journal (2022)
Programmable CRISPR-Cas9 microneedle patch for long-term capture and real-time monitoring of universal cell-free DNA
Nature Communications (2022)
Nature Reviews Microbiology (2022)
CPT1A-mediated fatty acid oxidation promotes cell proliferation via nucleoside metabolism in nasopharyngeal carcinoma
Cell Death & Disease (2022)